Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with Hereditary TTR Amyloidosis in the U.S.

- Ionis plans to open multiple sites in the U.S. CARLSBAD, Calif., Oct. 27, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it plans to open an expanded access program (EAP) for eligible patients with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy in the coming months. Ionis plans to open the first wave of EAP sites in the U.S.

The release as fetched from its publisher. ionis.com ↗